Implications of Medicaid Expansion Highlights AJPB Week in Review

By Davy James, Managing Editor

Top articles of the week from The American Journal of Pharmacy Benefits.

Related Videos
View All
Related Content

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

January 28th 2023

Pharmacy Focus: Student Edition - Career in PBMs

January 23rd 2023

MIS Biomarker May Effectively Anticipate Outcome of Immune Checkpoint Inhibitors for Colorectal Cancer

January 27th 2023

BONUS: Public Health Matters - Highlighting Women of Color in Pharmacy

January 19th 2023

Panel: Collaboration, Increased Naloxone Availability Can Help Prevent Opioid-Related Deaths

January 27th 2023

January OTC Case Studies- Diabetes

January 27th 2023

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

January 28th 2023

Pharmacy Focus: Student Edition - Career in PBMs

January 23rd 2023

MIS Biomarker May Effectively Anticipate Outcome of Immune Checkpoint Inhibitors for Colorectal Cancer

January 27th 2023

BONUS: Public Health Matters - Highlighting Women of Color in Pharmacy

January 19th 2023

Panel: Collaboration, Increased Naloxone Availability Can Help Prevent Opioid-Related Deaths

January 27th 2023

January OTC Case Studies- Diabetes

January 27th 2023

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

January 28th 2023

Pharmacy Focus: Student Edition - Career in PBMs

January 23rd 2023

MIS Biomarker May Effectively Anticipate Outcome of Immune Checkpoint Inhibitors for Colorectal Cancer

January 27th 2023

BONUS: Public Health Matters - Highlighting Women of Color in Pharmacy

January 19th 2023

Panel: Collaboration, Increased Naloxone Availability Can Help Prevent Opioid-Related Deaths

January 27th 2023

January OTC Case Studies- Diabetes

January 27th 2023
About Us
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.